Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies

Virology

Volumn 426, Issue 1, 2012, Pages 34-41

  Ringe, Rajesh ^a   Phogat, Sanjay ^b,c   Bhattacharya, Jayanta ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

Envelope; HIV 1; N linked glycosylation; Neutralizing antibody; PG16; PG9; V2 loop

Indexed keywords

GLYCAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BETA SHEET; CHIMERA; CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; ENVELOPE GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; POLYSACCHARIDES; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857791012     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.01.011     Document Type: Article

References (34)

1. Bunnik E.M., Pisas L., van Nuenen A.C., Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 2008, 82(16):7932-7941.
2. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., Wyatt R., Sodroski J. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 1997, 71(12):9808-9812.
3. Chackerian B., Rudensey L.M., Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 1997, 71(10):7719-7727.
4. Chen B., Vogan E.M., Gong H., Skehel J.J., Wiley D.C., Harrison S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433(7028):834-841.
5. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Kwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201(9):1407-1419.
6. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 2010, 84(20):10510-10521.
7. Doores K.J., Fulton Z., Hong V., Patel M.K., Scanlan C.N., Wormald M.R., Finn M.G., Burton D.R., Wilson I.A., Davis B.G. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(40):17107-17112.
8. Duenas-Decamp M.J., Clapham P.R. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J. Virol. 2010, 84(18):9608-9612.
9. Edwards T.G., Hoffman T.L., Baribaud F., Wyss S., LaBranche C.C., Romano J., Adkinson J., Sharron M., Hoxie J.A., Doms R.W. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J. Virol. 2001, 75(11):5230-5239.
10. Fischer P.B., Collin M., Karlsson G.B., James W., Butters T.D., Davis S.J., Gordon S., Dwek R.A., Platt F.M. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 1995, 69(9):5791-5797.
11. Go E.P., Irungu J., Zhang Y., Dalpathado D.S., Liao H.X., Sutherland L.L., Alam S.M., Haynes B.F., Desaire H. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J. Proteome Res. 2008, 7(4):1660-1674.
12. Gruters R.A., Neefjes J.J., Tersmette M., de Goede R.E., Tulp A., Huisman H.G., Miedema F., Ploegh H.L. Interference with HIV induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 1987, 330:74-77.
13. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
14. Land A., Zonneveld D., Braakman I. Folding of HIV-1 envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage. FASEB J. 2003, 17(9):1058-1067.
15. Li Y., O'Dell S., Walker L.M., Wu X., Guenaga J., Feng Y., Schmidt S.D., McKee K., Louder M.K., Ledgerwood J.E., Graham B.S., Haynes B.F., Burton D.R., Wyatt R.T., Mascola J.R. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 2011, 85(17):8954-8967.
16. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
17. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Kwon Y.D., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480(7377):336-343.
18. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., Bandawe G., Mlisana K., Abdool Karim S.S., Williamson C., Morris L. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5(9):e1000598.
19. Mukhopadhyay S., Ringe R., Patil A.A., Paranjape R.S., Bhattacharya J. Characterization of circulating HIV-1 env genes in plasma of two antiretroviral naive slow progressing patients with broad neutralizing antibody response with evidence of recombination. AIDS Res. Hum. Retroviruses 2011, EPub Ahead of Print, PMID: 21916806. doi:10.1089/aid.2011.0238.
20. Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 24:739-769.
21. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., Depetris R., Katpally U., Marozsan A., Cupo A., Maloveste S., Liu Y., McBride R., Ito Y., Sanders R.W., Ogohara C., Paulson J.C., Feizi T., Scanlan C.N., Wong C.H., Moore J.P., Olson W.C., Ward A.B., Poignard P., Schief W.R., Burton D.R., Wilson I.A. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334(6059):1097-1103.
22. Ringe R., Thakar M., Bhattacharya J. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naive Indian patients with recent infection. Retrovirology 2010, 7(1):76.
23. Ringe R., Sharma D., Zolla-Pazner S., Phogat S., Risbud A., Thakar M., Paranjape R., Bhattacharya J. A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. Virology 2011, 418:123-132.
24. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J.L., Derdeyn C.A. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 2007, 81(3):1350-1359.
25. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80(19):9586-9598.
26. van Gils M.J., Bunnik E.M., Burger J.A., Jacob Y., Schweighardt B., Wrin T., Schuitemaker H. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 2010, 84(7):3576-3585.
27. van Gils M.J., Bunnik E.M., Boeser-Nunnink B.D., Burger J.A., Terlouw-Klein M., Verwer N., Schuitemaker H. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 2011, 85(14):6986-6995.
28. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
29. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Principal Investigators P.G., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
30. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
31. Wilen C.B., Parrish N.F., Pfaff J.M., Decker J.M., Henning E.A., Haim H., Petersen J.E., Wojcechowskyj J.A., Sodroski J., Haynes B.F., Montefiori D.C., Tilton J.C., Shaw G.M., Hahn B.H., Doms R.W. Phenotypic and immunologic comparison of Clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 2011, 85(17):8514-8527.
32. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
33. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 1995, 69(9):5723-5733.
34. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(5993):811-817.